Highlights of the In Vitro Sections of the Draft ICH Drug Interaction Studies M12 Guideline and Comparison with Current Guidance

Join a 54-minute webinar led by Dr. Brian Ogilvie, VP of Scientific Consulting at BioIVT, exploring the critical aspects of the draft ICH Drug Interaction Studies M12 Guideline released in June 2022. Gain valuable insights into the harmonized global guidelines for drug interaction studies, comparing them with current FDA, EMA, and PMDA guidance documents. Learn about the development impacts of this new guideline, understand key differences from existing regulatory frameworks, and discover effective strategies for drug development that align with ICH M12 requirements. Led by an experienced toxicologist with extensive research publications and speaking engagements, master the essential knowledge needed to navigate the upcoming changes in drug interaction studies regulation, scheduled for adoption in early 2024.